公开(公告)号：US20140205679A1

公开(公告)日：2014-07-24

申请号：US13972800

申请日：2013-08-21

Applicant: SUNESIS PHARMACEUTICALS, INC.

Inventor： Jeffrey A. Silverman

IPC: A61K31/4375 ,  A61K31/282 ,  A61K45/06 ,  A61K33/24

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/555 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof.

Abstract translation: 公开了治疗，预防或治疗癌症的方法。 所述方法包括与第二活性剂组合施用SNS-595。 在某些实施方案中，治疗方法包括与顺铂，卡铂，吉西他滨或其组合组合施用SNS-595。

公开(公告)号：US20190047986A1

公开(公告)日：2019-02-14

申请号：US15911546

申请日：2018-03-05

Applicant: Sunesis Pharmaceuticals, Inc. ,  Biogen MA Inc.

Inventor： Brian T. HOPKINS ,  Timothy R. CHAN ,  Tracy J. JENKINS ,  Patrick CONLON ,  Xiongwei CAI ,  Michael HUMORA ,  Xianglin SHI ,  Ross A. MILLER ,  Andrew THOMPSON

IPC: C07D401/14

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

公开(公告)号：US10189817B2

公开(公告)日：2019-01-29

申请号：US15875629

申请日：2018-01-19

Applicant: BIOGEN MA INC. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Brian T. Hopkins ,  Xiongwei Cai ,  Timothy R. Chan ,  Patrick Conlon ,  Michael Humora ,  Tracy J. Jenkins ,  J. Michael Macphee ,  Xianglin Shi ,  Ross A. Miller ,  Andrew Thompson

IPC: C07D401/14 ,  C07D401/04 ,  C07D211/56 ,  C07D207/28 ,  C07D207/16

Abstract: The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

公开(公告)号：US09969730B2

公开(公告)日：2018-05-15

申请号：US15267911

申请日：2016-09-16

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Anantha Sudhakar ,  Jeff Jacobs ,  Ahmad Hashash ,  Sean Ritchie ,  Hengqin Cheng

IPC: A61K31/4375 ,  C07D471/04 ,  C07D417/14

CPC classification number: C07D471/04 ,  A61K31/4375 ,  C07D417/04 ,  C07D417/14

Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.

公开(公告)号：US09944622B2

公开(公告)日：2018-04-17

申请号：US15196389

申请日：2016-06-29

Applicant: Biogen MA Inc. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Brian T. Hopkins ,  Timothy R. Chan ,  Tracy J. Jenkins ,  Patrick Conlon ,  Xiongwei Cai ,  Michael Humora ,  Xianglin Shi ,  Ross A. Miller ,  Andrew Thompson

IPC: A61K31/506 ,  C07D401/14

CPC classification number: C07D401/14

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

公开(公告)号：US20180098975A1

公开(公告)日：2018-04-12

申请号：US15714988

申请日：2017-09-25

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Daniel C. Adelman ,  Jeffrey A. Silverman ,  Michelle Arkin ,  Jennifer Hyde ,  Duncan Walker ,  Jasmin Wright

IPC: A61K31/4375 ,  A61K45/06 ,  A61K31/513

CPC classification number: A61K31/4375 ,  A61K31/513 ,  A61K45/06

Abstract: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

公开(公告)号：US09920048B2

公开(公告)日：2018-03-20

申请号：US15380515

申请日：2016-12-15

Applicant: Millennium Pharmaceuticals, Inc. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Weirong Chen ,  Jennifer Cossrow ,  Lloyd Franklin ,  Bing Guan ,  John Howard Jones ,  Gnanasambandam Kumaravel ,  Benjamin Lane ,  Adam Littke ,  Alexey Lugovskoy ,  Hairuo Peng ,  Noel Powell ,  Brian C. Raimundo ,  Hiroko Tanaka ,  Jeffrey Vessels ,  Thomas Wynn ,  Zhili Xin

IPC: C07D239/28 ,  C07D417/14 ,  A61K45/06 ,  A61K31/506 ,  C07D417/12 ,  A61K31/5377 ,  C07D413/14 ,  C07D473/00 ,  A61K31/52 ,  C07D471/04 ,  C07F9/6558 ,  A61K31/675 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12

CPC classification number: C07D417/14 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04 ,  C07F9/65583

Abstract: The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.

公开(公告)号：US20180065974A1

公开(公告)日：2018-03-08

申请号：US15698171

申请日：2017-09-07

Applicant: Sunesis Pharmaceuticals, Inc. ,  Biogen MA Inc.

Inventor： Minna BUI ,  Patrick CONLON ,  Julio H. CUERVO ,  Daniel A. ERLANSON ,  Junfa FAN ,  Bing GUAN ,  Brian T. HOPKINS ,  Tracy J. JENKINS ,  Gnanasambandam KUMARAVEL ,  Alexey A. LUGOVSKOY ,  Doug MARCOTTE ,  Noel POWELL ,  Daniel SCOTT ,  Laura SILVIAN ,  Art TAVERAS ,  Deping WANG ,  Min ZHONG

IPC: C07D487/14 ,  C07D487/04 ,  C07D473/34 ,  C07D471/04

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

公开(公告)号：US20170373636A9

公开(公告)日：2017-12-28

申请号：US14462439

申请日：2014-08-18

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： MICHELLE ARKIN ,  JENNIFER HYDE ,  DUNCAN WALKER ,  JASMIN WRIGHT

IPC: H02S40/44 ,  A61K31/7048 ,  H02S40/38 ,  H01L31/052 ,  F24J2/51 ,  F24J2/40 ,  F24J2/24 ,  A61K45/06 ,  A61K38/15 ,  A61K33/24 ,  A61K31/7068 ,  H01L31/054 ,  A61K31/704 ,  A61K31/585 ,  A61K31/52 ,  A61K31/519 ,  A61K31/513 ,  A61K31/4375 ,  A61K31/407 ,  A61K31/395 ,  A61K31/337 ,  A61K31/282 ,  F24J2/34

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/337 ,  A61K31/395 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/555 ,  A61K31/585 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/15 ,  A61K38/1816 ,  A61K41/00 ,  A61K45/06 ,  A61K47/12 ,  C07D471/04 ,  F24S10/70 ,  F24S50/40 ,  F24S60/30 ,  F24S80/60 ,  H01L31/0547 ,  H02S40/38 ,  Y02E10/40 ,  Y02E10/52 ,  A61K2300/00

Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.

公开(公告)号：US20170368041A1

公开(公告)日：2017-12-28

申请号：US15642195

申请日：2017-07-05

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Glenn Michelson

IPC: A61K31/4375 ,  A61K39/395 ,  A61K31/706 ,  A61K31/513 ,  A61K38/19 ,  A61K38/18 ,  A61K31/7068 ,  C07D471/04 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K31/4375 ,  A61K31/513 ,  A61K31/706 ,  A61K31/7068 ,  A61K38/18 ,  A61K38/19 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  C07D471/04 ,  A61K2300/00

Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.